Skip to main content

Dyne Therapeutics, Inc.

DYN
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001818794

In the last 90 days, Dyne Therapeutics, Inc. insiders filed 0 open-market purchases and 10 sales; 245 institutions reported holding it in 13F filings for Q2 2026, worth $4.23B in total; no superinvestor holds it.

13F holders, Q4 2023

Institutional positions in Dyne Therapeutics, Inc. as of Dec 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

Institutional holders
124
+11 vs. Q3 2023
Shares held
69.9M
+10.2M (+17.0%) vs. Q3 2023
Total value
$930.0M
+$394.6M (+73.7%) vs. Q3 2023
New holders
25
43 more added
Sold out
14
40 more reduced

1 institution that held it in Q3 2023 haven't filed for Q4 2023 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.

Compare with Q3 2023: new holders, sold out and not filed yet

Holders and value by quarter

Institutions reporting DYN on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ4 2023: 124 institutions
Q1 2021: 75 institutionsQ2 2021: 76 institutionsQ3 2021: 83 institutionsQ4 2021: 93 institutionsQ1 2022: 94 institutionsQ2 2022: 90 institutionsQ3 2022: 102 institutionsQ4 2022: 113 institutionsQ1 2023: 127 institutionsQ2 2023: 118 institutionsQ3 2023: 114 institutionsQ4 2023: 124 institutionsQ1 2024: 169 institutionsQ2 2024: 193 institutionsQ3 2024: 200 institutionsQ4 2024: 200 institutionsQ1 2025: 205 institutionsQ2 2025: 198 institutionsQ3 2025: 207 institutionsQ4 2025: 233 institutionsQ1 2026: 228 institutionsQ2 2026: 245 institutions
Value heldQ4 2023: $930.0M
Q1 2021: $533.3MQ2 2021: $753.4MQ3 2021: $572.8MQ4 2021: $568.3MQ1 2022: $456.6MQ2 2022: $320.7MQ3 2022: $565.8MQ4 2022: $576.2MQ1 2023: $628.7MQ2 2023: $665.9MQ3 2023: $536.6MQ4 2023: $930.0MQ1 2024: $2.71BQ2 2024: $3.92BQ3 2024: $4.03BQ4 2024: $2.63BQ1 2025: $1.29BQ2 2025: $1.22BQ3 2025: $1.97BQ4 2025: $3.48BQ1 2026: $3.40BQ2 2026: $4.23B
Institutions holding DYN and their total value by quarter
QuarterHoldersValue
Q2 2026245$4.23B
Q1 2026228$3.40B
Q4 2025233$3.48B
Q3 2025207$1.97B
Q2 2025198$1.22B
Q1 2025205$1.29B
Q4 2024200$2.63B
Q3 2024200$4.03B
Q2 2024193$3.92B
Q1 2024169$2.71B
Q4 2023124$930.0M
Q3 2023114$536.6M
Q2 2023118$665.9M
Q1 2023127$628.7M
Q4 2022113$576.2M
Q3 2022102$565.8M
Q2 202290$320.7M
Q1 202294$456.6M
Q4 202193$568.3M
Q3 202183$572.8M
Q2 202176$753.4M
Q1 202175$533.3M

Institutions, Q4 2023

Shares, value and share of portfolio for each institution holding Dyne Therapeutics, Inc.; share changes are against Q3 2023.

Institutions holding DYN in Q4 2023
InstitutionSharesValue% of portfolioChange in sharesAction
Armistice Capital, LLC824,000$11.0M0.29%−376,000−31.3%Reduced
Commodore Capital LP900,000$12.0M1.05%+900,000New
Geode Capital Management, LLC932,838$12.4M0.00%+75,128+8.8%Added
Sofinnova Investments, Inc.1,013,505$13.5M0.76%+328,372+47.9%Added
Vivo Capital, LLC1,035,136$13.8M1.13%00.0%Unchanged
Goldman Sachs Group Inc1,160,772$15.4M0.00%−347,370−23.0%Reduced
Frazier Life Sciences Management, L.P.1,184,840$15.8M0.84%+1,184,840New
Artal Group S.A.1,217,960$16.2M0.55%+402,875+49.4%Added
FMR LLC1,282,812$17.1M0.00%+436,452+51.6%Added
TCG Crossover Management, LLC1,650,150$21.9M2.43%00.0%Unchanged
Wasatch Advisors Inc1,684,517$22.4M0.12%−3,285−0.2%Reduced
Logos Global Management LP1,880,000$25.0M2.78%−300,000−13.8%Reduced
Franklin Resources Inc1,913,832$25.5M0.01%+8760.0%Added
Deep Track Capital, LP2,000,000$26.6M0.93%−403,672−16.8%Reduced
Morgan Stanley2,021,395$26.9M0.00%+1,913,653+1,776.1%Added
Vida Ventures Advisors, LLC2,074,787$27.6M32.85%−145,247−6.5%Reduced
VR Adviser, LLC2,173,913$28.9M1.98%00.0%Unchanged
Vanguard Group Inc2,329,641$31.0M0.00%−34,673−1.5%Reduced
State Street Corp2,337,141$31.1M0.00%+398,499+20.6%Added
Citadel Advisors LLC3,053,440$40.6M0.04%+11,834+0.4%Added
BlackRock Inc.3,788,682$50.4M0.00%+481,717+14.6%Added
MPM Asset Management LLC4,951,303$65.9M32.36%00.0%Unchanged
FCPM III Services B.V.6,131,079$81.5M24.03%+6,131,079New
Atlas Venture Life Science Advisors, LLC9,885,449$131.5M15.66%00.0%Unchanged
Altium Capital Management LP0$00.00%−315,000−100.0%Sold out
Walleye Capital LLC0$00.00%−280,276−100.0%Sold out
ExodusPoint Capital Management, LP0$00.00%−184,010−100.0%Sold out
Two Sigma Investments, LP0$00.00%−24,400−100.0%Sold out
Walleye Trading LLC0$00.00%−24,326−100.0%Sold out
TD Asset Management Inc0$00.00%−23,000−100.0%Sold out
Marshall Wace, LLP0$00.00%−22,052−100.0%Sold out
Cornercap Investment Counsel Inc0$00.00%−20,938−100.0%Sold out
Corton Capital Inc.0$00.00%−19,926−100.0%Sold out
Balyasny Asset Management LLC0$00.00%−17,646−100.0%Sold out
AQR Capital Management LLC0$00.00%−11,644−100.0%Sold out
Spire Wealth Management0$00.00%−400−100.0%Sold out
EverSource Wealth Advisors, LLC0$00.00%−90−100.0%Sold out
Nisa Investment Advisors, LLC0$00.00%−35−100.0%Sold out
International Biotechnology Trust PLC––––Not filed